Isoniazid Adherence Reduces Mortality and Incident Tuberculosis at 96 Weeks Among Adults Initiating Antiretroviral Therapy With Advanced Human Immunodeficiency Virus in Multiple High-Burden Settings

BACKGROUND: People with human immunodeficiency virus (HIV) and advanced immunosuppression initiating antiretroviral therapy (ART) remain vulnerable to tuberculosis (TB) and early mortality. To improve early survival, isoniazid preventive therapy (IPT) or empiric TB treatment have been evaluated; how...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Amita, Sun, Xin, Krishnan, Sonya, Matoga, Mitch, Pierre, Samuel, McIntire, Katherine, Koech, Lucy, Faesen, Sharlaa, Kityo, Cissy, Dadabhai, Sufia S, Naidoo, Kogieleum, Samaneka, Wadzanai P, Lama, Javier R, Veloso, Valdilea G, Mave, Vidya, Lalloo, Umesh, Langat, Deborah, Hogg, Evelyn, Bisson, Gregory P, Kumwenda, Johnstone, Hosseinipour, Mina C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314898/
https://www.ncbi.nlm.nih.gov/pubmed/35899273
http://dx.doi.org/10.1093/ofid/ofac325

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314898/
https://www.ncbi.nlm.nih.gov/pubmed/35899273
http://dx.doi.org/10.1093/ofid/ofac325

Ejemplares similares